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SUMMARY
MicroRNAs are emerging as important regulators of diverse biological processes and pathologies
in animals and plants. While hundreds of human miRNAs are known, only a few have known
functions. Here we predict human microRNA functions by using a new method that systematically
assesses the statistical enrichment of several miRNA targeting signatures in annotated gene sets
such as signaling networks and protein complexes. Some of our top predictions are supported by
published experiments, yet many are entirely new or provide mechanistic insights to known
phenotypes. Our results indicate that coordinate miRNA targeting of closely connected genes is
prevalent across pathways. We use the same method to infer which microRNAs regulate similar
targets and provide the first genome-wide evidence of pervasive co-targeting, where a handful of
“hub” microRNAs are involved in a majority of co-targeting relationships. Our method and
analyses pave the way to systematic discovery of microRNA functions.
INTRODUCTION
MicroRNAs (miRNAs) regulate diverse biological processes in animals and plants (Bushati
and Cohen, 2007) and are among the most abundant regulatory factors in the human
genome, comprising 3–5% of known human genes (Griffiths-Jones et al., 2008). miRNAs
recognize target mRNAs by imperfect base pairing to sites in the 3′ untranslated region (3′
UTR), usually with perfect pairing of the miRNA seed region (nucleotides 2–8), ultimately
leading to translational repression and/or mRNA degradation (Bushati and Cohen, 2007).
Thousands of human genes are predicted to be targeted by miRNAs (Rajewsky, 2006),
suggesting that miRNAs play a pervasive role in the regulation of gene expression.
Although hundreds of human miRNAs have been identified and new ones are continually
being discovered (Griffiths-Jones et al., 2008), the function of most miRNAs remains
unknown. Increasingly, miRNA expression changes are being linked to phenotypes, but the
mechanistic role of the miRNA in the underlying biological network is often unclear. Given
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that many human miRNAs can target up to thousands of genes, how often do miRNAs target
a set of related genes to regulate a specific pathway or process? While recent studies show
that a few miRNAs have pathway-specific functions (Xiao and Rajewsky, 2009), earlier
work suggests that miRNAs primarily serve to fine-tune and confer robustness upon the
expression of many genes (Bartel and Chen, 2004; Farh et al., 2005; Stark et al., 2005).
The prevalence of multiple miRNAs targeting the same gene (“co-targeting”) is also unclear.
While many genes contain putative binding sites for multiple miRNAs (Krek et al., 2005;
Stark et al., 2005), many putative sites may not be functional in vivo. More specifically, the
combinations of miRNAs that function together by regulating common targets are unknown.
Knowledge of such co-targeting relationships would also enable one to infer a miRNA’s
function from the function of its co-targeting miRNAs.
Typically miRNA function is predicted by assessing whether the predicted targets of a given
miRNA are enriched for particular functional annotations. Such an approach has several
limitations: (1) target prediction is imperfect and can lead to spurious targets (Rajewsky,
2006); (2) having a subset of one’s favorite pathway genes in the putative target set does not
necessarily mean that the miRNA functions in the pathway; (3) predicted target sets are
often so large (hundreds to thousands of genes) and have such heterogeneous functional
annotations that standard algorithms are not sufficiently sensitive to make high-confidence
predictions. Rather than progressing from a miRNA to a potentially spurious target set that
may or may not have enriched function, here we introduce a computational method called
mirBridge, which starts with a gene set of known function, then assesses whether functional
sites for a given miRNA are enriched in the gene set compared to random gene sets with
similar properties.
We apply mirBridge to a variety of annotated gene sets for signaling pathways, diseases,
drug treatments, and protein complexes. We also use mirBridge to infer miRNA pairs that
tend to function together by regulating common targets and use the results to assemble a
miRNA-miRNA co-targeting network. Together, our analyses provide: (1) hundreds of
miRNA function predictions, many of which are supported by published experiments; (2)
genome-wide evidence that many miRNAs coordinately regulate multiple components of
pathways or protein complexes; and (3) evidence that miRNA co-targeting is prevalent, with
a small number of “hub” miRNA families involved in a large fraction of the co-targeting
interactions. Both the mirBridge method and the predictions it has generated can serve as
important resources for the future experimental dissection of miRNA functions.
RESULTS
mirBridge: linking miRNAs to gene sets
Many gene sets contain tens to hundreds of putative targets for any particular miRNA.
However, for a variety of reasons (e.g. mRNA secondary structure occludes binding, or the
miRNA and the target are not expressed together) many target sites are not functional in
vivo. The goal of mirBridge is to infer whether an unusually large proportion and number of
putative target sites for a miRNA (m) in a given gene set (G) are likely to be functional in
vivo. Towards this end, mirBridge computes a score by combining the results of three
statistical tests that evaluate different aspects of likely-functional target-site enrichment in
G. It is essential that the enrichment of sites in G be compared to enrichment in appropriate
control gene sets. Below we describe the individual tests and the method for constructing the
control gene sets (see Supplemental Experimental Procedures for details).
The following definitions are essential to the methodology of mirBridge. First, any gene
with one or more seed-matched site for m in its 3′ UTR is deemed a “putative target.”
Tsang et al. Page 2
Mol Cell. Author manuscript; available in PMC 2011 June 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Second, seed-matched sites can be classified into two categories (Figure 1A): “conserved
sites” (CS) are sites that are conserved across mammalian genomes; “high-context scoring
sites” (HCS) are sites with a context score above a predefined threshold. The context score
reflects the likelihood of a seed-matched site to confer repression based on several features,
including the distance of the site from the stop codon, accessibility of the site based on
secondary structure, and the extent of base pairing beyond the seed (Grimson et al., 2007).
The first test used by mirBridge, called “conservation enrichment signature” (CE), infers
whether the number of CS in G is significantly higher than that of random gene sets
containing the same number of putative targets as G. This test is similar to evaluating
whether the sites have evolved at a slower rate compared to random putative target sets, but
is fundamentally different from prior tests that utilize sequence conservation (Lewis et al.,
2005; Stark et al., 2005) (see Supplemental Experimental Procedures). The second test,
called “context-score signature” (CTX), evaluates whether the number of HCS is
significantly higher than that of random gene sets containing the same number of putative
targets as G. The CTX test is designed to detect enrichment of sites in G that are likely
functional but not necessarily conserved. The third test, called “site occurrence signature”
(OC), evaluates whether the number of putative target sites in G is unusually high compared
to random gene sets containing the same number of genes. While target site abundance alone
is not necessarily indicative of functional targeting by m, functional targeting enrichment
becomes a likely scenario even when G tests as moderately significant for the CE and/or
CTX tests. Note that both CE and CTX are based on comparison with random gene sets with
the same number of putative targets to detect enrichment in the proportion rather than the
number of CS or HCS. This ensures that the comparisons are valid, as gene sets with more
putative targets tend to have more CS or HCS. Since true positives are more likely than false
positives to test as simultaneously significant across the tests, we combine the three tests and
form a composite score (“OC-CE-CTX”) to increase sensitivity without sacrificing
specificity.
We developed a nearest-neighbor gene sampling algorithm, motivated by the principle of
kernel-based density estimators (Wegman, 1972), to generate random gene sets that are
similar to the input gene set with respect to general conservation level, 3′ UTR length, and
GC content, which primarily bias the CE, OC, and CTX tests, respectively. Simultaneous
adjustment is particularly important because these factors are correlated with each other
across genes. Specifically, for the OC test, comparable random gene sets are generated by
replacing each member of G with a randomly drawn gene that has similar GC content, 3′
UTR length, and general conservation level (Figure 1B). To ensure that the number of
putative targets in the random gene sets is the same as that in G for the CE and CTX tests,
the same nearest-neighbor procedure is used but only putative targets in G are replaced by
random putative targets (Figure 1C).
Finally, to obtain the OC-CE-CTX p value, the p values of the individual tests are combined
using a customized version of the inverse-normal method that corrects for dependencies
among tests (Joachim, 1999). When multiple gene sets and/or miRNAs are tested
simultaneously, multiple hypothesis testing is corrected by computing the false discovery
rate (FDR) using the q-value method (Storey and Tibshirani, 2003). “FDR” and “q value”
are used interchangeably below.
Besides 3′ UTR length, GC content, and general conservation, other less apparent factors
could bias mirBridge results, but their effects are likely small (see Supplemental
Experimental Procedures). The statistical model in mirBridge was also designed to
incorporate additional factors if needed – in principle any number of factors can be
accounted for by our nearest-neighbor sampling procedure.
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mirBridge is fundamentally different from testing whether the number of predicted miRNA
targets in a gene set is significantly higher than expected using the Fisher’s Exact Test
(FET), a standard way to assess the significance of gene set overlaps. First, mirBridge takes
gene set properties into account; second, it combines different and important biological
characteristics of target sites; and finally, it uses metrics (CE and CTX) that focus on the
proportion of likely-functional target sites instead of the number of predicted target overlaps.
In fact, mirBridge has superior sensitivity and specificity compared to FET as shown in the
applications below.
Inferring human miRNA functions
To link human miRNA families (miRNAs with a shared seed sequence) to functions, we
applied mirBridge to gene sets from (1) canonical signaling pathways from MSigDB
(Subramanian et al., 2005); (2) KEGG (Kanehisa and Goto, 2000); (3) human protein
complexes from the CORUM database (Ruepp et al., 2008); (4) gene co-expression modules
(Segal et al., 2004); (5) Gene Ontology (GO) Biological Process; (6) GO Component; and
(7) GO Function (Ashburner et al., 2000). At a FDR cutoff of 0.2, mirBridge predicts 185,
128, 1198, 456, 432, 71, and 175 distinct miRNA-function associations, respectively (Tables
S1a–g). Most predictions implicate pathways or protein complexes with multiple putative
targets for the miRNA, whereas some have only one (or very few) putative targets
containing multiple high-quality sites (e.g. miR-33 and statin pathway). The latter fits the
paradigm implied in some recent papers where a miRNA phenotype seems to be accounted
for by one (or just a few) targets: “miR-X regulates process Y by targeting gene Z.”
However, the prevalence of coordinate targeting of multiple related genes suggests that most
miRNAs exert their phenotypic effects by targeting multiple network components.
To facilitate a succinct discussion of such a large set of predictions, Table 1 shows a
selection of predictions that either already have support from the literature or wherein the
predicted pathway (1) has known activity in the tissue where the miRNA is known to be
expressed; or (2) represents core cellular processes (e.g. “apoptosis”) and has a large number
of putative targets for the miRNA. We also favor predictions that reoccur in closely related
or synonymous gene sets, e.g. “cell cycle” and “G1 to S transition.”
mirBridge is sensitive to biological signals and can independently uncover known miRNA
functions
Although mirBridge is not trained on any dataset of known miRNA functions, several of the
top hits already have experimental support in the literature (Table 1A), such as the
association of miR-16 with the cell cycle, Wnt signaling and prostate cancer (Calin et al.,
2005; Linsley et al., 2007) (Figure S1A). This is also an example where mirBridge links a
disease and the pathways underlying its pathology: miR-16 has been shown to work through
the Wnt pathway to function as a tumor suppressor in prostate cancer (Bonci et al., 2008).
Analogously, miR-7 hits the ErbB pathway in glioblastoma (Kefas et al., 2008; Webster et
al., 2009); miR-221/222 hits the estrogen signaling pathway in breast cancer (Miller et al.,
2008; Zhao et al., 2008); and let-7 hits the G1-S cell-cycle pathway in breast cancer (Schultz
et al., 2008; Yu et al., 2007). mirBridge can also implicate a pathway of interest given the
tissue specificity of a miRNA: miR-7 is predicted to regulate the insulin receptor pathway
and is known to be highly expressed in insulin-producing cells of pancreatic islets (Bravo-
Egana et al., 2008; Correa-Medina et al., 2009; Joglekar et al., 2009). mirBridge also
independently uncovered feedback loops: miR-146 is predicted to target several upstream
signaling genes in the NF-kB pathway while its transcription is known to be activated by
NF-kB (Taganov et al., 2006) (Figure S1B). Another notable prediction supported by the
literature is miR-34 targeting BCL2 and several additional anti-apoptotic genes in the BAD
pathway (Chang et al., 2007; Cloonan et al., 2008; He et al., 2007). This prediction provides
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an attractive hypothesis for how miR-34 upregulation could lead to apoptosis. In sum, these
results are reassuring and indicate that mirBridge can capture biologically relevant signals.
mirBridge is significantly more sensitive than the standard approach of evaluating gene set
overlaps using FET. For instance, when FET is applied to the canonical pathway gene sets,
only five predictions can be made at the 0.2 FDR cutoff (Table S1h); all five have FDRs
above 0.18 and only one has support from the literature (miR-16 and the Gleevec pathway
given that miR-16 is associated with leukemia). Furthermore, none of the top mirBridge
predictions supported by published experiments were uncovered. For example, for miR-16,
none of the cell-cycle related pathways are ranked near the top even if we ignore the
statistical significance and order the pathways within each miRNA family by their q values
(the top cell-cycle related entry has rank 54, q=0.55). These results suggest that mirBridge
can better uncover biologically relevant signals than FET.
It is important to note that the comprehensiveness of our predictions is dependent on the
gene sets used. Some known miRNA functions are not in our predicted list because the
appropriate gene set(s) were not included in the analysis. For example, miR-200 is known to
function in the epithelial-mesenchymal transition (Burk et al., 2008; Gregory et al., 2008a;
Korpal et al., 2008a; Park et al., 2008), but none of the gene sets used in our analysis
captures this process. However, when mirBridge is applied to genes whose function
annotation in the GeneCards database includes “epithelial-mesenchymal transition,”
miR-141/200a has the lowest q value among all miRNAs (q=0.08).
To further assess the ability of mirBridge to predict known miRNA functions independently,
we compiled eight additional miRNA phenotypes from the literature and applied mirBridge
to seemingly relevant gene sets from KEGG or GeneCards (Table S2). Of nine phenotypes,
four miRNA-gene set p values are significant and two are marginally significant (Table 2).
In a multiple hypothesis testing context where all miRNAs are tested simultaneously for the
phenotype gene set, however, only two would have been predicted at a FDR cutoff of 0.2
even though the desired miRNA ranks at or near the top for all four of the significant cases.
This suggests that for these specific gene sets, mirBridge is sensitive to the relevant
biological signals but lacks sufficient statistical power after multiple-testing correction. It
follows that the hundreds of low-FDR predictions that are made by mirBridge are
compelling candidates for experimental follow-up given that these emerged in the
simultaneous testing of thousands of miRNA-gene set combinations. We expect the
statistical power of mirBridge to continue to improve as additional genomes and knowledge
of miRNA-target interactions become available.
We also sought to understand cases where mirBridge failed to predict the correct functions.
Closer examination of the three failed cases in Table 2 suggests that for let-7 and miR-133
the gene sets used do not capture the biology relevant to the miRNA targeting. The cell
cycle may be a key pathway through which let-7 exerts its effect on lung cancer (Esquela-
Kerscher et al., 2008; Kumar et al., 2008; Schultz et al., 2008), but the non-small cell lung
cancer gene set lacks most cell cycle genes and other postulated targets such as HMGA2 and
MYC (let-7 does hit the G1-S cell-cycle transition pathway; Table 1A). Similarly for
miR-133 and cardiac hypertrophy: two out of the three known targets relevant to the
phenotype are not in the GeneCards set (CDC42 and WHSC2; (Care et al., 2007)). Finally,
for miR-122, it turns out that inhibition of miR-122 by antagomir treatment tends to
downregulate, rather than upregulate, cholesterol biosynthetic genes (Krutzfeldt et al.,
2005), suggesting that the effect of miR-122 on cholesterol biosynthetic genes is indirect.
Thus the insignificant mirBridge p value for miR-122 and cholesterol biosynthesis genes is
not surprising.
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mirBridge provides many new miRNA function predictions
The majority of mirBridge predictions are not yet directly supported by existing experiments
(Tables 1B and S1–4). Some pathways predicted in common for multiple miRNAs seem
particularly compelling because the miRNAs are known to be co-regulated. For example,
the apoptosis pathway is predicted for miR-23 and -24, which are different in sequence but
are co-expressed from the same cluster (Chhabra et al., 2009). Some predictions seem
reasonable based on the function of the miRNA host gene. For example, the statin/
cholesterol homeostasis pathway is linked to miR-33, which is embedded in an intron of a
transcription factor that regulates cholesterol synthesis and uptake (Figure S1C). Other
predictions seem plausible based on known miRNA functions with similar developmental
placement and timing. For example, axon guidance pathways are predicted for miR-124,
which has already been shown to positively regulate neurogenesis (Cheng et al., 2009;
Visvanathan et al., 2007). Consistently, miR-124 was linked to the SNARE protein complex
as it putatively targets VAMP3, a component of SNARE, via three conserved and high
context-scoring sites; VAMP3 is known to function in the docking and fusion of synaptic
vesicles with the presynaptic membrane (Sudhof, 2004).
mirBridge predictions can also provide mechanistic interpretations of published
experiments. For example, it is known that activation of PIP3 signaling leads to the
hypertrophic response in cardiac myocytes and that miR-1 expression is down-regulated
upon hypertrophic stress (Care et al., 2007; Heineke and Molkentin, 2006; Sayed et al.,
2007). mirBridge links miR-1 to the PIP3 pathway, and the putative miR-1 targets in the
pathway are all pro-hypertrophic except PTPN1 (Table 1A), suggesting that the down-
regulation of miR-1 helps to drive pathway activation (Figure 2). Post-transcriptional
repression by miR-1 could allow these genes to be transcribed at higher (or leaky) levels
without triggering a hypertrophic response, such that a reduction in miR-1 expression would
suffice to rapidly activate signaling at multiple levels. For example, de-repression of the
most downstream factors (e.g. CDC42) could quickly lead to sarcomere remodeling, a first
step in the hypertrophic response (Nagai et al., 2003). Increasing levels of upstream factors
coupled with positive feedback loops would intensify the response.
We envision a useful application of mirBridge would be to probe function of interest guided
by the expression profile of likely relevant miRNAs. Since we are interested in
neurotransmitter and axon guidance pathways, we applied mirBridge to manually curated
gene sets for these pathways and examined miRNAs known to be expressed in the brain (see
Supplemental Experimental Procedures). miR-218 is a top hit for both GABA and glutamate
gene sets (q=0.025 and 0.033, respectively). That these two neurotransmitter activities may
be regulated by the same miRNA is intriguing given that glutamate and GABA are,
respectively, the major excitatory and inhibitory neurotransmitters, and that the latter can be
enzymatically converted from the former. In addition, encouraged by the recent finding that
miR-218 is enriched at synapses of hippocampal neurons, we tested a gene set for the
presynaptic cytomatrix protein complex (Siegel et al., 2009). miR-218 is the top hit with a q
value of 0.0008. In sum, the mirBridge hits for these gene sets extend early experimental
findings to implicate miR-218 as potential regulators of neuronal activity at hippocampal
synapses.
miRNA co-targeting is prevalent
Our miRNA-pathway map indicates that some miRNAs function in the same pathway(s) by
targeting a similar set of genes. Indeed, many miRNAs may function together (via “co-
targeting”) to regulate target-gene expression. To assess the prevalence of co-targeting and
infer which miRNAs are co-targeting partners, we next used sets of genes likely regulated
by particular miRNAs to create a miRNA-to-miRNA mapping. Specifically, our inputs to
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mirBridge were the predicted target sets (PTS) of 73 deeply conserved human miRNA
families. We call a miRNA family Y a “co-targeting partner” of a miRNA family X if at
least one of Y’s seed-matched sequences has a significant mirBridge q value in the PTS of X
and denote the relationship as “X→Y.” We predicted co-targeting relationships for all
ordered pairs of the 73 families (73 × 72 = 5256 distinct pairs).
Our results indicate that miRNA co-targeting is prevalent: 221 distinct X→Y co-targeting
relationships are inferred at a FDR cutoff of 0.2 (Table S3a). A subset of these predictions
correspond to miRNA genomic clusters (Yu et al., 2006), such as the miR-19b-2/106a
cluster on Xq26.2 and the miR-17-18-19a-20-92 cluster on 13q31.3 (Table S3b). Co-
targeting pairs in close genomic proximity are not surprising: these miRNAs are
polycistronic and co-expressed, and are thus likely to function together to regulate common
targets. In fact, clustered miRNAs are enriched for co-targeting relationships: when X and Y
are members of a genomic cluster, they are predicted as co-targeting partners 25% of the
time compared to 3% when X and Y are not clustered. Consequently, the median q-value of
clustered pairs is significantly lower than that of unclustered ones (p < 2.1 × 10−7, Mann-
Whitney Test; see Table S3c for the clusters used in this analysis), indicating that our
method for detecting co-targeting is sensitive, specific, and capable of uncovering
biologically relevant signals.
If our predictions reflect bona fide biological signals, we also expect a significant percentage
of the X→Y pairs to possess mutual co-targeting relationships, i.e. each miRNA’s putative
binding sites would have a score below the FDR cutoff in the other miRNA’s PTS. Indeed,
96/221 (43%) of the X→Y predicted pairs do. While the remaining 57% of the X→Y pairs
do not have the corresponding Y→X pairs falling below the FDR cutoff, there is nonetheless
a significant correlation between their q values (Spearman correlation = 0.42 (p=0); Figure
S2). Also, the reciprocal (Y→X) q values of significant X→Y pairs are lower than those of
pairs with q values greater than 0.2 (p < 5 × 10−140 Mann-Whitney Test). The general
reciprocation of co-targeting scores indicates that a significant percentage of our predictions
are specific and that the signals we are detecting are likely biologically relevant.
We also tested whether co-targeting relationships could be inferred from gene set overlaps,
where the X→Y q value was computed using FET on the number of genes shared between
the PTSs of the miRNA family pair. This analysis failed to provide informative results
because almost all tested pairs have a significant q value: 2264 (86%) and 2628 (100%) of
the pairs have a q value of less than 0.05 by using the Bonferroni and FDR correction,
respectively. This suggests that a core set of genes are frequently predicted as targets for
many miRNA family pairs; these likely correspond to genes with highly conserved 3′ UTRs
and/or low GC content, properties that favor a gene being predicted as a target using
Targetscan. This result strongly suggests that the degree of PTS overlap is not sufficiently
specific to detect authentic co-targeting relationships, whereas mirBridge has superior
specificity and thus able to provide biologically relevant signals as shown above.
Network analysis of co-targeting interactions
Our co-targeting predictions can naturally be organized as a network where the nodes are
miRNA families and the directed edges between nodes denote the X→Y predictions. A
network representation enables examination of connectivity patterns beyond pairwise
interactions. We first checked whether the edges in the network are evenly distributed across
nodes or concentrated around a few nodes (“hubs”). Strikingly, the edges connecting the 10
most connected nodes (out of 69 nodes with at least one adjacent edge) account for more
than 55% (123/221) of the edges in the network (Figure 3A and Table S3d). While overall
the size of a miRNA family’s PTS is correlated to its connectivity ranking (p = 10−6
Spearman correlation), this correlation becomes insignificant when restricted to families
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with at least 900 predicted targets (p > 0.1). Since only six of the top 40 most-connected
families have fewer than 900 predicted targets, the size of a miRNA family’s PTS alone
cannot explain the connectivity pattern among the top 40 families. The hub miRNA families
probably have functions in diverse contexts. For example, some hubs have a large number of
members and therefore are likely to have more diverse functions depending on the spatial-
temporal expression of individual miRNAs (e.g. miR-93.hd/291-3p/
294/295/302/372/373/520).
We reasoned that groups of tightly inter-connected nodes might represent miRNAs that
perform similar functions. To identify such groups we used a graph clustering tool that
ignores edge weights to identify tightly interconnected nodes (Bader and Hogue, 2003)
(Figure 3B). We find that subnetwork 1 has four families and is the largest and most highly
interconnected; three of the families (miR-17-5p, -130, -93.hd) are among the most
connected families (Figure 3A). This subnetwork is also well-connected to subnetwork 3
(miR-18, -19, -181), probably because miR-17-18-19-20 are co-expressed from a
polycistronic transcript. The miR-17 cluster is known to be overexpressed in a number of
human cancers, including B-cell tumors, while miR-142 is also highly expressed in B cells
(Chen and Lodish, 2005; Mendell, 2008). Their shared PTS is enriched for genes in
developmental processes (p < 3.8 × 10−5), consistent with the miR-17 cluster’s function in
the development of B cells, the heart and lungs (Mendell, 2008; Ventura et al., 2008). Our
linking of the miR-142 and miR-130/301 families—whose functions are largely unknown—
to the miR-17 cluster suggests that these miRNA families also participate in similar
developmental and oncogenic processes.
DISCUSSION
We have introduced a systematic method for inferring miRNA functions by assessing the
enrichment of likely functional target sites in gene sets. Key features of mirBridge include
combining test metrics that detect different aspects of functional targeting, and a sampling
algorithm for removing gene-set biases to improve estimation of statistical significance.
Hundreds of human miRNA-function associations were inferred by mirBridge; some are
reassuringly supported by published experiments, but many are not previously known and/or
provide mechanistic insights beyond published data.
Our results provide hints about the general principles of miRNA-mediated regulation in
networks. While some miRNAs could act as global regulators by repressing up to thousands
of targets genome-wide (Lewis et al., 2005), many appear to have pathway-specific
functions, and these miRNAs tend to target multiple genes in the same pathway. Typically,
the predicted targets of the miRNA are genes that drive pathway activity in a coherent
direction (e.g. miR-16 targeting of G1-to-S-promoting genes). Such coordinate targeting
could partially explain how individual miRNAs can be potent effectors of pathway activity
even though the amount of repression conferred by miRNAs tends to be modest for any
single target (Baek et al., 2008; Selbach et al., 2008; Xiao and Rajewsky, 2009). As was
observed earlier (Martinez et al., 2008; Tsang et al., 2007), some of our predictions (e.g.
miR-1) involve miRNAs mediating feedback and feedforward loops, whose functions
include protein homeostasis and signal amplification, respectively. For example, miRNAs
could be “master” regulators of pathways and thus serve as effective therapeutic targets
because positive feedbacks could amplify small changes in protein concentration conferred
by miRNA targeting of multiple genes. Our analysis also indicates that miRNAs can
function in, and mediate cross-talk among, multiple canonical pathways, such as miR-16’s
potential roles across the cell cycle and Wnt pathways to coordinately regulate cellular
growth and proliferation.
Tsang et al. Page 8
Mol Cell. Author manuscript; available in PMC 2011 June 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mirBridge also facilitates context-specific target prediction: one can first predict which
pathways a miRNA regulates and then compile high-quality putative targets within a
pathway. This strategy may be especially effective for miRNAs that function in only a few
pathways, as targets predicted genome-wide may have low specificity (Lewis et al., 2005).
Additional filtering can be used to strengthen the target predictions, for example, by
requiring that the putative target and the miRNA be significantly correlated in their
expression using miRNA-mRNA expression data sets (Lu et al., 2005) (Table S1i).
In addition to providing functional links across miRNAs, our human miRNA-miRNA map
provides, to the best of our knowledge, the first genome-wide evidence that miRNA co-
targeting is prevalent, and that a handful of hub miRNA families are involved in a large
fraction of the co-targeting connections. The abundance of co-targeting further suggests that
while individual miRNAs may provide only modest levels of repression, combinatorial
targeting by multiple miRNAs (Krek et al., 2005) can potentially achieve a wide range of
target-level modulations. Given that multiple miRNAs are expressed at different levels in
any given cell type, individual genes can evolve combinations of miRNA binding sites to
optimize expression levels across cell types (Bartel and Chen, 2004). miRNA target sites are
short and could thus be acquired or lost relatively quickly over evolution to fine-tune gene
expression levels.
Designating a group of miRNAs as “co-targeting” does not necessarily imply that these
miRNAs are co-expressed so as to regulate their common targets at the same time and place.
In fact, the exact opposite is also likely: different miRNAs are responsible for controlling a
given set of targets in different contexts. In general, a combination of the above scenarios is
likely for individual cases, and additional data (e.g. miRNA and target expression profiles)
are needed to further dissect the mechanistic basis of individual co-targeting predictions.
mirBridge is currently limited to assessing enrichment at the level of miRNA families using
seed-matched motifs. But this is largely due to our lack of general understanding of miRNA-
target interaction beyond seed pairing and features captured by the context score. In
principle, the mirBridge methodology is general and can be applied to any combinations of
gene sets, sequence motifs and site scoring metrics, including non-miRNA motifs, such as
those involved in regulating mRNA stability. Given mirBridge’s ability to simultaneously
correct for multiple gene-set biases, and the increasing availability of genomes and
annotated gene sets, mirBridge is poised to serve as a key resource for the comprehensive
functional dissection of miRNAs and other regulatory sequence motifs in genomes.
EXPERIMENTAL PROCEDURES
Seed-matched site compilation
miRNA family memberships, 3′ UTR sequences, seed-matched sites and their context scores
and conservation status were downloaded from TargetScan
(http://www.targetscan.org/vert_40/). For each known human gene, the number of seed-
matched sites for each miRNA family, the number of those that are conserved, and the
context score were computed. Since the context score depends on the full miRNA sequence,
the context score for a miRNA family is defined as the average of all human members of
that family.
mirBridge
The method as described in the text was implemented in Matlab. More details and related
discussions can be found in Supplementary Experimental Procedures.
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miRNA function analysis
Canonical signaling pathway and KEGG gene sets were downloaded from
http://www.broad.mit.edu/gsea/msigdb/index.jsp. The cancer, CORUM, and GO sets were
downloaded from http://robotics.stanford.edu/~erans/cancer/,
http://mips.helmholtz-muenchen.de/genre/proj/corum, and NCBI Gene, respectively. To
reduce noise and avoid spurious annotations, we only used GO annotations with
experimental and peer-reviewed evidence. A miRNA-gene set prediction requires at least
one of the miRNA seed motifs (m2-8 and/or m7-A) to test as significant in the gene set. The
q value reported for individual miRNAs corresponds to the q value of the seed motif with
the smaller p value.
miRNA family selection
The deeply conserved miRNAs are ones that are conserved across human, mouse, rat, dog
and chicken. We focused on these miRNAs because they probably have (1) more conserved
functions, (2) a larger number of targets compared to less-conserved miRNAs, and (3)
stronger conservation enrichment signals.
Target prediction
Targets were compiled for each miRNA by including genes with at least one conserved
seed-match (across human, mouse, rat and dog) or a seed-match with a context score of
greater than 68 in the 3′ UTR (see Supplemental Experimental Procedures). Predictions
based on context score alone were included because functional target sites can be
imperfectly conserved. High-quality putative targets in gene sets (Table 1 and S1) were
compiled using the same definition.
X→Y predictions and analysis
mirBridge was applied to the predicted target set of each miRNA family. Only the seed-
matched motifs of the 73 families were scored. When both seed-matched motifs of a miRNA
family are tested significant, the smaller q value is used as the X→Y q value. Human
miRNA clusters were obtained from (Yu et al., 2006).
Predicted target set overlap analysis
The number of overlaps between the predicted target set of each miRNA-family pair was
computed. The statistical significance was computed using Fisher’s Exact Test (see
Supplemental Experimental Procedures).
Predicted target set and pathway overlap analysis
Similar to above except that (1) all genes that are not predicted as a target for any miRNA
were removed from the pathway gene sets; and (2) the population size is taken as the
number of genes that are predicted as a target for at least one miRNA family and belong to
at least one pathway.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. mirBridge overview
(A) The input to mirBridge is a set of genes. Red and blue squares denote conserved and
non-conserved seed-matched sites in the 3′ UTR respectively. The number inside the squares
denotes the context score. For each miRNA target sequence of interest, mirBridge computes
the N, K, H, and T as illustrated. (B) The procedure for evaluating whether N is significantly
higher than that of comparable random gene sets (the OC test). To obtain the null
distribution for N, random gene sets with similar 3′ UTR properties were constructed by
replacing each gene in the original set (g1, … gn; solid red dots) by a randomly drawn gene
(r1, r2, … rn). The probability that ri is drawn to replace gi is inversely proportional to its
distance to gi in the 3-D space defined by 3′ UTR length, GC content and general
conservation level. The histogram depicts the null distribution of N for miR-16 in the cell-
cycle gene set. (C) The procedure for evaluating whether K and H are significantly higher
than those of random gene sets containing T putative targets with similar 3′ UTR properties
as the putative targets in G (the CE and CTX tests, respectively). The same gene sampling
procedure from (B) is used except that only the putative targets in G (empty red dots) are
replaced by random putative targets (empty gray dots) so that T is identical across G and the
random gene sets. The histograms depict the null distributions of K and H, respectively, for
random gene sets with T=5 putative targets for the miR-16 and the cell-cycle gene set.
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Figure 2. miR-1 and PIP3 signaling in cardiac hypertrophy
The orange repressive arrows depict high-quality putative targets of miR-1 in the PIP3
pathway in cardiac myocytes (see Experimental Procedures). The rest of the network is
based on known interactions compiled from the literature (Heineke and Molkentin, 2006).
See Figure S1 for network diagrams of other selected predictions discussed in the text.
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Figure 3. The miRNA-cotargeting network inferred by mirBridge
The thickness of the edges is proportional to −log (q). (A) The ten most connected nodes
and the adjacent edges are highlighted in yellow and red, respectively. (B) Examples of
highly interconnected subnetworks. See also Figure S3.
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Table 1A
Selected mirBridge predictions with published evidence (see Table S1 for more details). “High-quality
putative targets” are ones with either a conserved or high context-scoring site (see Experimental Procedures).
miRNA Function q value High-quality putative targets Evidence
146 IL1 receptor, NFKB, Toll Like
Receptor signaling
0 TRAF6, IRAK1, TLR4 (Jones et al.,
2009; Taganov
et al., 2006)
15/16/195/424/497 Cell cycle; G1 to S 0
CCNE1, CCND1, CCND3, CCND2,
CDC25A (Linsley et al.,
2007; Liu et
al., 2008)CCNE1, WEE1, E2F3, CCND1,
CCND3, CCND2, CDC25A
29 Collagen 0 COL4A1, COL4A5, COL4A4,
COL4A6, COL4A2, COL4A3, FGA
(Li et al.,
2009; van
Rooij et al.,
2008)
7 ErbB signaling; glioma 0
RAF1, EGFR, FRAP1, MAPK1,
PIK3CD, PAK1, PIK3R3, RPS6KB1,
CAMK2D, PAK2, TGFA, PTK2,
CBL, ERBB4, CRKL, MAPK3 (Kefas et al.,2008; Webster
et al., 2009)RAF1, RB1, CALM3, EGFR,
FRAP1, MAPK1, PIK3CD, PIK3R3,
CAMK2D, TGFA, IGF1R, MAPK3
7 insulin signaling 0.000208 IRS1, IRS2, RAF1, CALM3, FRAP1,
MAPK1, PHKA2, PIK3CD, PIK3R3,
RPS6KB1, MKNK1, CBL, FLOT2,
PRKAG2, CRKL, SOCS2,
PPARGC1A, MAPK3
(Bravo-Egana
et al., 2008;
Correa-
Medina et al.,
2009; Joglekar
et al., 2009)
15/16/195/424/497 Wnt pathway 0.0356 FZD10, DVL1, CCND1, PAFAH1B1,
PPP2R5C, FZD6, CCND3, DVL3,
MAPK9, PRKCI, CCND2, WNT7A,
FOSL1, WNT2B
(Bonci et al.,
2008)
103/107 TNF pathway 0.0522 HRB, CASP3, TNF, MAP3K7,
TNFAIP3, NR2C2
(Xie et al.,
2009)
122 NO1 pathway 0.0546 SLC7A1, RYR2, CALM3, TNNI1 (Yang and
Kaye, 2009)
15/16/195/424/497 prostate cancer 0.07345 CCNE1, AKT3, PIK3R1, MAP2K1,
IKBKB, E2F3, RAF1, CCND1,
PIK3R3, CHUK, CCNE1, FGFR1,
FGFR2, GRB2, FOXO1, IGF1R,
BCL2, CREB5, MAPK3
(Bonci et al.,
2008)
135 TGF beta signaling 0.07389 SMAD5, ROCK2, SMURF2, THBS2,
ROCK1, SMAD2, FKBP1A,
NODAL, PPP2R1B, INHBA,
TGFBR1, ACVR1B, BMPR1A, SP1,
RPS6KB1, BMPR2, RUNX2, RBX1,
SKI
(Li et al.,
2008)
34a/449 Notch signaling 0.07389 NOTCH1, DLL1, NUMBL, HDAC1,
JAG1, NOTCH2, NOTCH3
(Ji et al., 2008;
Ji et al., 2009)
21 cytokine-cytokine receptor interaction 0.0865 IL12A, CCL20, CCL1, FASLG,
TNFRSF11B, TNFRSF10B, IL1B,
CCR7, LEPR, BMPR2, XCL1, LIFR,
CNTFR, TGFBR2, CXCL5,
ACVR2A
(Lu et al.,
2009)
1/206 PIP3 signaling in cardiac myocytes 0.0977 IGF1, CREB5, YWHAZ, MET,
CDC42, YWHAQ, PTPN1, PREX1
(Care et al.,
2007; Sayed et
al., 2007)
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miRNA Function q value High-quality putative targets Evidence
17-5p/20/93.mr/106/519.d cell cycle; G1 to S 0.122
CCNE1, CCND1, CDC25A, SMAD3
(Cloonan et
al., 2008;
Pickering et
al., 2009)
CCNG2, RBL1, RPA2, WEE1, E2F1,
CCND2, CDKN1A, MCM3,
CDC25A, RB1, E2F3, CCND1,
CCNE2
221/222 breast cancer estrogen signaling 0.1432 KIT, CDKN1B, NFYB, SERPINB5,
ESR1, THBS1, THBS2
(Miller et al.,
2008; Zhao et
al., 2008)
34/449 BAD pathway (apoptosis) 0.1499 KIT, KITLG, BCL2, IGF1, PRKACB (Chang et al.,
2007; Cloonan
et al., 2008;
He et al.,
2007)
let-7/98 breast cancer estrogen signaling 0.1595 CYP19A1, NGFB, CDH1, TP53,
CDKN1A, FASLG, PPIA, THBS1,
DLC1, PAPPA, IL6, DLC1, DST,
PAPPA, CND1
(Schultz et al.,
2007)
let-7/98 G1 to S 0.1871 E2F6, TP53, PRIM2, CDKN1A,
CDC25A, RB1, CCND2, CCND1,
CCND2, CCND2
(Schultz et al.,
2008; Yu et
al., 2007)
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Table 1B
Selected new mirBridge miRNA function predictions (see Table S1 for details). Same format as Table 1A
miRNA Function q value High-quality putative targets
33 statin pathway 0.00155 ABCA1, HMGCR
203 G alpha i pathway 0.00532 MAPK1, JUN, PCLD, SRC, MYEF2,
F2RL2, PLD2, EPHB2
23 apoptosis 0.00801 CHUK, APAF1, CASP7, CASP3, BCL2,
BIRC4, IRF1, BNIP3L, LMNB1
205 tight junction 0.01195 PRKCE, CLDN11, EPB41, CNKSR3,
INADL, YES1, VAPA, MAGI2, PARD6G,
CLDN8, PTEN, PRKCH, MLLT4, ACTB,
PRKCA, PARD6B
187 antigen processing and presentation 0.02192 KIR2DL2, KIR2DL1, KIR2DS2, KIR2DS4,
KIR2DS5, KIR2DL4, KIR2DL3, IFNA2,
KIR2DL5A
219 nuclear receptors 0.02806 THRB, NR2C2, NR1I2, NR5A2, NR3C1,
NR2C2, ESR1
17-5p/20/93.mr/106/519.d JNK MAPK pathway 0.0377 MAP3K2, MAP3K5, MAP3K9, GAB1,
MAP3K12, NR2C2, ZAK, DUSP8, MAPK9,
DUSP10, MAP3K3, MAP3K11
124.2/506 axon guidance 0.04983 CHP, ROCK1, NFATC1, SEMA6D, ITGB1,
GNAI1, NRAS, GNAI3, SEMA6A, NRP1,
NFAT5, EPHB4, PLXNA3, EPHA3,
EPHA2, SEMA5A, ROCK2, SRGAP3,
EFNB3, EFNB1, NCK2, GNAI2, SEMA6C,
EFNB2
34a/449 glycosphingolipid biosynthesis 0.05144 FUT1, FUT5, FUT9, GCNT2, B4GALT2
128 GnRH signaling 0.05144 PRKY, PRKX, MAPK14, MAP2K7,
PLCB1, MAP2K4, ADCY8, ADCY2,
GRB2, HBEGF, EGFR, CDC42, ADCY6
24 cytokine-cytokine receptor interaction 0.05203 IFNG, EDA2R, TNFRSF19, CCR4, FASLG,
IL10RB, IL1A, CCR1, PDGFRA, PDGFRB,
EDA, PDGFC, TNFSF9, IL2RA, IL21R,
CX3CR1, IL8RB, EDAR, CCL18,
TNFRSF1A, IL1R1, IL8RA, IL29, IL2RB,
ACVR1B, FLT1, IL22RA2, IL19, TNF,
CSF1R, CNTFR, CLCF1,
33 PGC-1α pathway 0.0541 YWHAH, CAMK4, PPARA, MEF2C,
CAMK2G, PPP3CB, CAMK2G,
PPARGC1A
375 purine metabolism 0.0544 PDE4A, PDE8A, PDE5A, PDE7B, ADCY9,
PDE4D, PDE10A, POLR3G, PDE4D,
POLR2, AADCY6, PDE11A
141/200a EGF/PDGF pathway 0.0637 GRB2, MAP2K4, STAT5A, EGFR,
PRKCB1, CSNK2A1, JUN, TAL1
142-5p ubiquitin mediated proteolysis 0.07389 VHL, UBE2D1, SMURF1, CUL2, UBE2A,
WWP1, CUL3, UBE2B, CDC23, UBE2E3
101 ubiquitin mediated proteolysis 0.07681 UBE2D1, UBE2D2, UBE2A, VHL,
UBE2D3, UBE2G1, FBXW11, FBXW7,
CUL3
142-3p regulation of actin cytoskeleton 0.07816 ITGAV, APC, MYLK, RAC1, WASL,
MYH10, ROCK2, ITGB8, CRK, CFL2,
FGF23, MYH9
19 Ca signaling 0.07827 EDNRB, ADRB1, GRM1, CALM1,
CACNA1C, GRIN2A, CHP, SLC25A6,
SLC8A1, ADCY7, ITPR1, PDE1C, ADCY1,
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miRNA Function q value High-quality putative targets
ATP2B4, ADCY9, PRKACB, PLCB1,
SPHK2, ERBB4, ITPKB, PTK2B
24 apoptosis 0.1148 BNIP3L, BCL2L11, BIRC4, FASLG,
NFKBIE, HELLS, RIPK1, TRAF1,
CASP10, TNFRSF1A, TNF, IRF1, IRF5
135 integrin pathway 0.122 ROCK2, ITGA1, ITGA2, ARHGEF7, PTK2,
ARHGEF6, ROCK1, AKT3, PLCG1, PAK7,
ANGPTL2, RHO
93.HD/291-3P/294/295/302/372/373/520 nuclear receptors 0.1342 VDR, NR2C2, PPARA, ESR1, NR4A2,
NR2E1, NPM1, NR2F2
27 statin pathway 0.1396 ABCA1, LDLR, LPL, HMGCR
33 cell cycle 0.1555 CDK6, CCND2, CDC25A, RB1
383 O-glycan biosynthesis 0.1658 GALNT13, GALNT11, GCNT4, GALNT1,
GALNT7
148/152 inositol phosphate metabolism 0.1677 SYNJ1, PTEN, PI4KA, PIK3CA, ITPKB,
PLCB1, ITPK1
25/32/92/363/367 phosphatidylinositol signaling 0.1916 SYNJ1, PTEN, ITPR1, BMPR2, PIP5K3,
PIP5K1C, PIK3R1, PIK3R3, RPS6KA4,
PRKAR2B, PCTK1, PRKCE, PIP4K2C,
RPS6KB1, CALM3
30-3p ubiquitin mediated proteolysis 0.1928 UBE2J1, UBE2K, UBE2G1, UBE2D1,
UBE2D3
153 insulin receptor signaling 0.1934 GRB2, PIK3R1, RPS6KA3, RPS6KB1,
SORBS1, CAP1, IRS2, FOXO1, AKT3
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